Bench to bedside: pathophysiology of acute coronary syndromes and implications for therapy.

Our understanding of the pathophysiology of unstable angina (UA) and non-ST-segment elevation (NSTE) myocardial infarction (MI) [commonly referred to as NSTE acute coronary syndrome(s) (ACS)] has evolved considerably over the years, with atherothrombosis playing a pivotal role. This review discusses the molecular interactions in coronary thrombosis that may serve as therapeutic targets for more effective management of these syndromes. The purposes of this review are: 1) to discuss current understanding of the pathophysiology of NSTE ACS; 2) to describe recent studies with novel antithrombotic agents [e.g., low-molecular-weight heparin, thienopyridines, glycoprotein (GP) IIb-IIIa inhibitors] in patients with NSTE ACS; and 3) to highlight recommendations for management of patients with NSTE ACS in the recently updated American College of Cardiology (ACC)/ American Heart Association (AHA) guidelines, including the appropriate use of antithrombotic therapies.

[1]  R. Califf,et al.  Clinical significance of thrombocytopenia during a non-ST-elevation acute coronary syndrome. The platelet glycoprotein IIb/IIIa in unstable angina: receptor suppression using integrilin therapy (PURSUIT) trial experience. , 1999, Circulation.

[2]  R. Califf,et al.  Pharmacodynamics of chimeric glycoprotein IIb/IIIa integrin antiplatelet antibody Fab 7E3 in high-risk coronary angioplasty. , 1994, Circulation.

[3]  E. Topol,et al.  Antiplatelet and anticoagulant use after myocardial infarction , 1996, Clinical cardiology.

[4]  D. Fintel,et al.  Management of patients with non—ST‐segment elevation acute coronary syndromes: Insights from the pursuit trial , 2000, Clinical cardiology.

[5]  J. Downey,et al.  Favorable remodeling enhances recovery of regional myocardial function in the weeks after infarction in ischemically preconditioned hearts. , 2000, Circulation.

[6]  E. Ohman,et al.  Early clinical experience with integrelin, an inhibitor of the platelet glycoprotein IIb/IIIa integrin receptor. , 1995, European heart journal.

[7]  M. LeWinter,et al.  Protective effects of aspirin against acute myocardial infarction and death in men with unstable angina. Results of a Veterans Administration Cooperative Study. , 1983, The New England journal of medicine.

[8]  C. Madden.  Risk of myocardial infarction and death during treatment with low dose aspirin and intravenous heparin in men with unstable coronary artery disease: The RISC Group Lancet 336: 827–830 Oct 1990 , 1991 .

[9]  D. S. Neblock,et al.  Analysis of GPIIb/IIIa receptor number by quantification of 7E3 binding to human platelets. , 1996, Blood.

[10]  K. Stringer.  The Evolving Role of Platelet Glycoprotein IIb/IIIa Inhibitors in the Management of Acute Coronary Syndromes , 1999, The Annals of pharmacotherapy.

[11]  P. Shah,et al.  New insights into the pathogenesis and prevention of acute coronary syndromes. , 1997, The American journal of cardiology.

[12]  V. Fuster,et al.  Coronary plaque disruption. , 1995, Circulation.

[13]  D. Huse,et al.  Direct medical costs of coronary artery disease in the United States. , 1998, The American journal of cardiology.

[14]  D. Kereiakes,et al.  Time course, magnitude, and consistency of platelet inhibition by abciximab, tirofiban, or eptifibatide in patients with unstable angina pectoris undergoing percutaneous coronary intervention. , 1999, The American journal of cardiology.

[15]  E. Braunwald,et al.  Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban. , 2001, The New England journal of medicine.

[16]  N. Rao,et al.  7E3 monoclonal antibody directed against the platelet glycoprotein IIb/IIIa cross-reacts with the leukocyte integrin Mac-1 and blocks adhesion to fibrinogen and ICAM-1. , 1997, Arteriosclerosis, thrombosis, and vascular biology.

[17]  R. Califf,et al.  A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Study Group. , 1997 .

[18]  Catherine Sudlow,et al.  Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients , 2002, BMJ : British Medical Journal.

[19]  E. Topol,et al.  Platelet glycoprotein IIb/IIIa receptors in cardiovascular medicine. , 1995, The New England journal of medicine.

[20]  W. Weaver,et al.  Randomized, double-blind, placebo-controlled dose-ranging study of tirofiban (MK-383) platelet IIb/IIIa blockade in high risk patients undergoing coronary angioplasty. , 1996, Journal of the American College of Cardiology.

[21]  R. Jordan,et al.  Abciximab (ReoPro, Chimeric 7E3 Fab) Demonstrates Equivalent Affinity and Functional Blockade of Glycoprotein IIb/IIIa and αvβ3 Integrins , 1998 .

[22]  V. Fuster,et al.  Effect of an Eccentric Severe Stenosis on Fibrin(ogen) Deposition on Severely Damaged Vessel Wall in Arterial Thrombosis: Relative Contribution of Fibrin(ogen) and Platelets , 1994, Circulation.

[23]  D. Waters,et al.  Aspirin Versus Heparin to Prevent Myocardial Infarction During the Acute Phase of Unstable Angina , 1993, Circulation.

[24]  R. Virmani,et al.  Coronary plaque erosion without rupture into a lipid core. A frequent cause of coronary thrombosis in sudden coronary death. , 1996, Circulation.

[25]  Alan D. Lopez,et al.  Mortality by cause for eight regions of the world: Global Burden of Disease Study , 1997, The Lancet.

[26]  P. Libby,et al.  The unstable atheroma. , 1997, Arteriosclerosis, thrombosis, and vascular biology.

[27]  S. Borzak,et al.  Low-molecular-weight heparins in the management of acute coronary syndromes. , 1999, Archives of internal medicine.

[28]  H. Weisman,et al.  Monoclonal Antibodies to Platelet Glycoprotein IIb/IIIa as Antithrombotic Agents a , 1991, Annals of the New York Academy of Sciences.

[29]  S. Chierchia,et al.  Intermittent coronary occlusion in acute myocardial infarction. Value of combined thrombolytic and vasodilator therapy. , 1987, The New England journal of medicine.

[30]  M. Simoons.  Effect of glycoprotein IIb/IIIa receptor blocker abciximab on outcome in patients with acute coronary syndromes without early coronary revascularisation: the GUSTO IV-ACS randomised trial , 2001, The Lancet.

[31]  P. Théroux,et al.  Aspirin, heparin, or both to treat acute unstable angina. , 1988, The New England journal of medicine.

[32]  W. Gibler,et al.  Chest pain centers: diagnosis of acute coronary syndromes. , 2000, Annals of emergency medicine.

[33]  D. Sackett,et al.  Aspirin, sulfinpyrazone, or both in unstable angina. Results of a Canadian multicenter trial. , 1985, The New England journal of medicine.

[34]  R. Califf,et al.  Acute Coronary Syndromes in the GUSTO-IIb Trial Prognostic Insights and Impact of Recurrent Ischemia , 1998 .

[35]  A. Connor,et al.  The way I see it: House officers need formal career development , 2002 .

[36]  H. Weisman,et al.  Pharmacodynamic profile of short-term abciximab treatment demonstrates prolonged platelet inhibition with gradual recovery from GP IIb/IIIa receptor blockade. , 1998, Circulation.

[37]  M J Davies,et al.  A macro and micro view of coronary vascular insult in ischemic heart disease. , 1990, Circulation.

[38]  P. Jumes,et al.  Fibrinogen receptor antagonist-induced thrombocytopenia in chimpanzee and rhesus monkey associated with preexisting drug-dependent antibodies to platelet glycoprotein IIb/IIIa , 1999 .

[39]  R. Jordan,et al.  Abciximab Readministration: Results of the ReoPro Readministration Registry , 2001, Circulation.

[40]  E. Antman,et al.  Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) 11B trial. , 1999, Circulation.

[41]  Stgrp Capture,et al.  Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: the CAPTURE study , 1997, The Lancet.

[42]  Carl J Pepine,et al.  ACC/AHA 2002 guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction--summary article: a report of the American College of Cardiology/American Heart Association task force on practice guidelines (Committee on the Management of Patients , 2002, Journal of the American College of Cardiology.

[43]  Salim Yusuf,et al.  Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study , 2001, The Lancet.

[44]  D. Fitzgerald,et al.  Ticlopidine and clopidogrel. , 1999, Circulation.

[45]  Richard O. Hynes,et al.  Integrins: A family of cell surface receptors , 1987, Cell.

[46]  Integrilin to Minimise Platelet Aggregation and Coronary Thrombosis-II.  Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention: IMPACT-II , 1997, The Lancet.

[47]  R. Califf,et al.  Immediate and reversible platelet inhibition after intravenous administration of a peptide glycoprotein IIb/IIIa inhibitor during percutaneous coronary intervention. , 1995, The American journal of cardiology.

[48]  M. Cohen,et al.  Trials of glycoprotein IIb‐IIIa inhibitors in non‐st‐segment elevation acute coronary syndromes: Applicability to the practice of medicine in the united states , 1999, Clinical cardiology.

[49]  P. Libby,et al.  Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. , 1994, The Journal of clinical investigation.

[50]  S. Yusuf,et al.  Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. , 2001, The New England journal of medicine.

[51]  R. Califf,et al.  Prognostic importance of concomitant heparin with eptifibatide in acute coronary syndromes. PURSUIT Investigators. Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy. , 2001, The American journal of cardiology.